New York State Medicaid Policy and Billing Guidance for Pharmacy Reimbursement of COVID-19 Oral Antivirals
As of 7/20/2022

Updates are highlighted

Effective December 29, 2021, New York State (NYS) Medicaid will reimburse pharmacies for dispensing Coronavirus Disease 2019 (COVID-19) oral antivirals with no member cost-sharing. This policy applies to both Medicaid fee-for-service (FFS) and Medicaid Managed Care (MMC) to include Mainstream MMC Plans, HIV Special Needs Plans (HIV SNPs), and Health and Recovery Plans (HARPs).

Effective July 6, 2022, NYS will reimburse pharmacies for ordering and dispensing certain COVID-19 oral antivirals with no member cost sharing when ordered and dispensed according to an Emergency Use Authorization.

Coverage Policy:
- COVID-19 oral antivirals must be approved or granted Emergency Use Authorization (EUA) through the FDA and must be ordered in accordance with the FDA approval or authorization.
- Paxlovid™ (nirmatrelvir and ritonavir) must be prescribed for an individual patient by a physician, nurse practitioner, or physician assistant authorized under NYS law to prescribe oral antivirals, or a state-licensed pharmacist in accordance with the EUA for Paxlovid™.
- Lagevrio™ (molnupiravir) must be prescribed for an individual patient by a physician, nurse practitioner (NP), or physician assistant (PA) authorized under NYS law to prescribe oral antivirals.
- Prior authorization is not required.
- Providers are prohibited from charging NYS Medicaid members a co-payment or any cost-sharing responsibility for COVID-19 oral antivirals, consistent with other COVID-19 Medicaid guidance.

FFS Pharmacy Billing:
- To bill for the dispensing of COVID-19 oral antivirals, the pharmacy must submit a valid National Drug Code (NDC). NDCs are listed in the Emergency Use Authorization for each COVID-19 oral antiviral. Additionally, providers can also perform a search for each NDC using the eMedNY formulary search page.
- Pharmacies must bill with a cost of $10.09 and will be reimbursed a $10.08 dispensing fee.
Billing Instructions

<table>
<thead>
<tr>
<th>NCPDP D.0. Claim Segment Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>436-E1 (Product/Service ID Qualifier)</td>
<td>Enter a value of &quot;03&quot; (NDC)</td>
</tr>
<tr>
<td>444-E9 (Pharmacist ID)</td>
<td>Enter Pharmacist National Provider Identifier (NPI) number</td>
</tr>
<tr>
<td>411-DB (Prescriber ID)</td>
<td>Enter Prescriber NPI number*</td>
</tr>
<tr>
<td>461-EU (Prior Authorization Type Code)</td>
<td>Enter 04= Exempt Copay**</td>
</tr>
</tbody>
</table>

*Leave the field blank if the pharmacist is ordering the COVID-19 therapeutic.

**Claims submitted for COVID-19 related testing, evaluation, and treatment that do not adjudicate with a zero copayment can be systematically adjusted by utilizing the National Council for Prescription Drug Programs (NCPDP) field. This instruction can be found in the NCPDP D.0 Companion Guide, located on the eMedNY "5010/D.0 Transaction Instructions" web page.

Please see the July 2020 issue of the Medicaid Update for further guidance on origin code and serial number values that must be submitted on the claim. In the origin code field use “5” and the corresponding serial number of “99999999” for “Pharmacy dispensing” when applicable for non-patient specific orders.

MMC Pharmacy Billing
The COVID-19 oral antivirals’ billing guidance and reimbursement amounts are specific to Medicaid FFS. Individual MMC Plans should be contacted for their specific reimbursement and billing guidance. Plan information can be found by visiting the following website: Medicaid Managed Care Pharmacy Benefit Information Center.

Additional Information:
- Related to the EUA for Paxlovid™, including prescribing conditions, may be found in the FDA Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid™ document.
- New York State Education Department Office of the Professions COVID-19 guidance web page.
- Oral Antivirals Department of Health (ny.gov).
- Prioritization of mAbs during resource shortages_20211229.pdf (ny.gov).
- Related to the Public Health Emergency and COVID-19 Therapeutics, including antivirals and monoclonal antibodies, can be found here: COVID-19 Therapeutics.

Questions:
- For Medicaid FFS billing questions, please contact the eMedNY Call Center at (800) 343-9000.
- For Medicaid FFS Pharmacy Policy questions, please contact ppno@health.ny.gov.